Neven, P., Han, S. N. (2025). PROTAC SERD vepdegestrant outperforms fulvestrant for advanced-stage ER+HER2− breast cancer harbouring acquired ESR1 mutations. Nature Reviews Clinical Oncology. https://doi.org/10.1038/s41571-025-01062-6